Patents by Inventor Travis Wilson

Travis Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11998585
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Grant
    Filed: March 1, 2022
    Date of Patent: June 4, 2024
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson
  • Publication number: 20240156892
    Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
    Type: Application
    Filed: August 23, 2023
    Publication date: May 16, 2024
    Applicant: Stealth BioTherapeutics Inc.
    Inventors: D. Travis Wilson, Mark Bamberger
  • Publication number: 20240100119
    Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.
    Type: Application
    Filed: April 28, 2023
    Publication date: March 28, 2024
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20240059735
    Abstract: The disclosure provides methods of preventing or treating mitochondrial myopathy in a mammalian subject, reducing risk factors associated with mitochondrial myopathy, and/or reducing the likelihood or severity of mitochondrial myopathy. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: April 17, 2023
    Publication date: February 22, 2024
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20240024408
    Abstract: The disclosure generally describes methods of preventing or treating Lebers hereditary optic neuropathy (LHON). The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: February 8, 2023
    Publication date: January 25, 2024
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Patent number: 11771734
    Abstract: The disclosure provides methods of preventing or treating Barth Syndrome in a mammalian subject, reducing risk factors associated with Barth Syndrome, and/or reducing the likelihood or severity of Barth Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to increase expression of TAZ1 in subjects in need thereof.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: October 3, 2023
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventors: D. Travis Wilson, Mark Bamberger
  • Publication number: 20230279051
    Abstract: The disclosure provides methods of preventing, ameliorating or treating disruption of mitochondrial function and symptoms thereof. The methods provide administering aromatic-cationic peptides in effective amounts to prevent, treat or ameliorate the disruption of mitochondrial oxidative phosphorylation in a cell such as that found in a subject suffering from, or predisposed to a mitochondrial disease or disorder. In some embodiments, the methods comprise administering to a subject suffering from, or at risk for a mitochondrial disease or disorder, an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Application
    Filed: October 11, 2022
    Publication date: September 7, 2023
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20230190859
    Abstract: The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or seventy of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof.
    Type: Application
    Filed: June 13, 2022
    Publication date: June 22, 2023
    Applicants: Stealth BioTherapeutics Inc., Henry Ford Health Systems
    Inventors: D. Travis Wilson, Hani N. Sabbah
  • Patent number: 11672841
    Abstract: The disclosure provides methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia, and/or reducing the likelihood or severity of Friedreich's ataxia. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to e.g., reduce oxidative stress, increase mitochondrial metabolism, or a combination thereof.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: June 13, 2023
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson
  • Patent number: 11678137
    Abstract: A contact and ranging system includes a first device that includes a first transceiver, a second transceiver, and a controller to control the first transceiver and the second transceiver of the first device. The first device is operable to determine a distance between the first device and a second device. The first transceiver is configured to perform a discovery operation. Other devices are discovered and added to a list of paired devices. A ranging schedule for each paired device in the list of paired devices is determined. The second transceiver is configured to perform a ranging operation. The ranging and response transmissions are transmitted and received by a pair of devices, such that a range between the pair of devices is determined based upon a time of flight between the pair of devices. The range between the pair of devices is matched with a timestamp and stored in a database.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: June 13, 2023
    Assignee: Fleetwood Group, Inc.
    Inventors: Brian T. Harvey, Jason T. Grant, Travis Wilson, Nicholas Hayhoe, Warren Guthrie, Nicholas A. Schrock, John G. Videtich
  • Publication number: 20230109564
    Abstract: The disclosure provides methods of preventing or treating DMD in a mammalian subject, reducing risk factors associated with DMD, and/or reducing the likelihood or severity of DMD. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: May 3, 2022
    Publication date: April 6, 2023
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20230043587
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Application
    Filed: June 22, 2022
    Publication date: February 9, 2023
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20230033758
    Abstract: The disclosure provides methods for detecting and diagnosing diseases and conditions associated with defects in cardiolipin remodeling. In some embodiments, the present technology relates to methods for detecting the presence or amount of cardiolipin isoforms and/or the presence or amount of enzymes involved in cardiolipin remodeling.
    Type: Application
    Filed: March 30, 2022
    Publication date: February 2, 2023
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20220296672
    Abstract: The disclosure relates to methods for treating a subject suffering from hyperalgesia caused by drug-induced neuropathy by administering to the subject an effective amount of an aromatic-cationic peptide. The disclosure also relates to methods for protecting a subject from hyperalgesia caused by drug-induced neuropathy by administering an effective amount of an aromatic-cationic peptide to a subject at risk for developing the condition.
    Type: Application
    Filed: March 1, 2022
    Publication date: September 22, 2022
    Applicant: Stealth BioTherapeutics Inc.
    Inventor: D. Travis Wilson
  • Publication number: 20220296671
    Abstract: The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: February 25, 2022
    Publication date: September 22, 2022
    Applicants: Stealth BioTherapeutics Inc., Heart Institute Good Samaritan Hospital
    Inventors: D. Travis Wilson, Robert A. Kloner
  • Publication number: 20220280593
    Abstract: The invention provides methods of treating an obstructive coronary artery disease in a mammalian subject. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide to subjects in need thereof and performing a coronary artery bypass graft procedure on the subject.
    Type: Application
    Filed: October 29, 2021
    Publication date: September 8, 2022
    Applicant: Stealth BioTherapeutics Inc.
    Inventors: Kenneth Borow, D. Travis Wilson
  • Patent number: 11420998
    Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: August 23, 2022
    Assignees: Stealth Biotherapeutics Inc., Mayo Foundation for Medical Education and Research
    Inventors: D. Travis Wilson, Lilach O. Lerman, Stephen C. Textor
  • Patent number: 11376304
    Abstract: The present technology is directed to compositions and methods for preventing, ameliorating, or reducing the severity of one or more signs, or symptoms associated with a reduction of function, decreased expression level of, and/or deficiency in one or more of COL4A3, COL4A4 and COL4A5 genes. Also disclosed herein are methods of preventing or treating Alport Syndrome in a mammalian subject, reducing risk factors associated with Alport Syndrome, and/or reducing the likelihood or severity of Alport Syndrome. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: July 5, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson
  • Publication number: 20220194288
    Abstract: A tailgate assembly is provided for a cargo bed having a bottom wall and a front, left and right side walls. An opening is defined between the left and right side walls, and the bottom wall. The tailgate assembly includes a first panel and a second panel. The first panel is pivotally connected to the bottom wall. The first panel is pivotable between a cargo-retaining position and an unfolded position with respect to the bottom wall. In the cargo-retaining position, the first panel closes the opening. The second panel is pivotally connected to the first panel. The second panel is pivotable between a folded position and a ramp position. In the folded position, the first panel and the second panel are substantially parallel to one another and in the ramp position the first and second panels extend from one another at an angle greater than ninety degrees.
    Type: Application
    Filed: December 23, 2020
    Publication date: June 23, 2022
    Applicant: KUBOTA CORPORATION
    Inventors: Nicholas ALLICOCK, Fahmid SHARKAR, Hiroki BESSHO, Travis WILSON
  • Patent number: 11366104
    Abstract: The present technology provides methods for detecting and diagnosing diseases and conditions characterized by mitochondrial dysfunction using monocytes as an indicator of the dysfunction.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: June 21, 2022
    Assignee: STEALTH BIOTHERAPEUTICS INC.
    Inventor: D. Travis Wilson